Parathyroid Carcinoma and Adenoma Co-existing in One Patient: Case Report and Comparative Proteomic Analysis

Overview

Journal Cancer Genomics Proteomics

Specialties Biochemistry
Genetics
Oncology

Date 2021 Oct 26

PMID 34697069

Citations 5

Authors

Federica Ciregia

Filomena Cetani

Elena Pardi

Alessio Soggiu

Cristian Piras

Lorenzo Zallocco

Simona Borsari

Maurizio Ronci

Vanni Caruso

Claudio Marcocci

Maria Rosa Mazzoni

Antonio Lucacchini

Laura Giusti

Affiliations

Soon will be listed here.

Abstract

Background/aim: The lack of specific parathyroid carcinoma (PC) biomarkers in clinical practice points out the importance of analyzing the proteomic signature of this cancer. We performed a comparative proteomic analysis of PC and parathyroid adenoma (PA) co-existing in the same patient.

Patients And Methods: PC and PA were taken from a 63-year-old patient. Using two-dimensional differential gel electrophoresis (2D-DIGE) coupled to mass spectrometry we examined the differences between PC and PA proteins. For validation, additional PC and PA samples were obtained from 10 patients. Western blot analysis was used to validate the difference of expression observed with 2D-DIGE analysis. Bioinfomatic analysis was performed using QIAGEN's Ingenuity Pathways Analysis (IPA) to determine the predominant canonical pathways and interaction networks involved.

Results: Thirty-three differentially expressed proteins were identified in PC compared to PA. Among these, ubiquitin C-terminal hydrolase-L1 (UCH-L1) was highly overexpressed in PC. The result was confirmed by Western Blot analysis in additional PC samples.

Conclusion: Our comparative proteomic analysis of co-existing neoplasms allowed detecting specific and peculiar differences between PC and PA overcoming population biological variability.

Citing Articles

A Pilot Study of and Gene Variants in Primary Hyperparathyroidism.

Chorti A, Achilla C, Siasiaridis A, Aristeidis I, Cheva A, Theodosios P Balkan J Med Genet. 2025; 27(2):33-39.

PMID: 40070855 PMC: 11892936. DOI: 10.2478/bjmg-2024-0011.

UCHL1 Overexpression Is Related to the Aggressive Phenotype of Non-small Cell Lung Cancer.

Kim C, Lee E, Kwak S, Lee S, Kim E, Park M Tuberc Respir Dis (Seoul). 2024; 87(4):494-504.

PMID: 39362830 PMC: 11468449. DOI: 10.4046/trd.2023.0166.

An extremely rare case of nonfunctioning parathyroid carcinoma occurring in a parathyroid adenoma.

Nomura T, Moriya T, Miyoshi K Med Mol Morphol. 2023; 56(2):152-158.

PMID: 36912960 DOI: 10.1007/s00795-023-00350-3.

Applications of spatially resolved omics in the field of endocrine tumors.

Hou Y, Gao Y, Guo S, Zhang Z, Chen R, Zhang X Front Endocrinol (Lausanne). 2023; 13:993081.

PMID: 36704039 PMC: 9873308. DOI: 10.3389/fendo.2022.993081.

DIGE Analysis of Clinical Specimens.

Gelfi C, Capitanio D Methods Mol Biol. 2022; 2596:177-199.

PMID: 36378440 DOI: 10.1007/978-1-0716-2831-7_14.

References

Cetani F, Pardi E, Giovannetti A, Cerrai P, Borsari S, Vignali E . Six novel MEN1 gene mutations in sporadic parathyroid tumors. Hum Mutat. 2000; 16(5):445. DOI: 10.1002/1098-1004(200011)16:5<445::AID-HUMU12>3.0.CO;2-6. View

Guo J, Li X, Zhang W, Chen Y, Zhu S, Chen L . HSP60-regulated Mitochondrial Proteostasis and Protein Translation Promote Tumor Growth of Ovarian Cancer. Sci Rep. 2019; 9(1):12628. PMC: 6718431. DOI: 10.1038/s41598-019-48992-7. View

Sharma M . Annexin A2 (ANX A2): An emerging biomarker and potential therapeutic target for aggressive cancers. Int J Cancer. 2018; 144(9):2074-2081. DOI: 10.1002/ijc.31817. View

Wang Y, Zhou W, Wang J, Huang X, Zuo Y, Wang T . Arginine Methylation of MDH1 by CARM1 Inhibits Glutamine Metabolism and Suppresses Pancreatic Cancer. Mol Cell. 2016; 64(4):673-687. DOI: 10.1016/j.molcel.2016.09.028. View

Wulfkuhle J, Sgroi D, Krutzsch H, McLean K, McGarvey K, Knowlton M . Proteomics of human breast ductal carcinoma in situ. Cancer Res. 2002; 62(22):6740-9. View

Kumari N, Chaudhary N, Pradhan R, Agarwal A, Krishnani N . Role of Histological Criteria and Immunohistochemical Markers in Predicting Risk of Malignancy in Parathyroid Neoplasms. Endocr Pathol. 2016; 27(2):87-96. DOI: 10.1007/s12022-016-9426-7. View

Yamazaki T, Hibi K, Takase T, Tezel E, Nakayama H, Kasai Y . PGP9.5 as a marker for invasive colorectal cancer. Clin Cancer Res. 2002; 8(1):192-5. View

Kruijff S, Sidhu S, Sywak M, Gill A, Delbridge L . Negative parafibromin staining predicts malignant behavior in atypical parathyroid adenomas. Ann Surg Oncol. 2013; 21(2):426-33. DOI: 10.1245/s10434-013-3288-8. View

Pennington K, Chan T, Torres M, Andersen J . The dynamic and stress-adaptive signaling hub of 14-3-3: emerging mechanisms of regulation and context-dependent protein-protein interactions. Oncogene. 2018; 37(42):5587-5604. PMC: 6193947. DOI: 10.1038/s41388-018-0348-3. View

10.

Park W, Chung K, Young M, Kim S, Lee Y, Lee E . Differential protein expression of lymph node metastases of papillary thyroid carcinoma harboring the BRAF mutation. Anticancer Res. 2013; 33(10):4357-64. View

11.

Xiang T, Li L, Yin X, Yuan C, Tan C, Su X . The ubiquitin peptidase UCHL1 induces G0/G1 cell cycle arrest and apoptosis through stabilizing p53 and is frequently silenced in breast cancer. PLoS One. 2012; 7(1):e29783. PMC: 3261155. DOI: 10.1371/journal.pone.0029783. View

12.

Peretti M, Angelini M, Savalli N, Florio T, Yuspa S, Mazzanti M . Chloride channels in cancer: Focus on chloride intracellular channel 1 and 4 (CLIC1 AND CLIC4) proteins in tumor development and as novel therapeutic targets. Biochim Biophys Acta. 2014; 1848(10 Pt B):2523-31. DOI: 10.1016/j.bbamem.2014.12.012. View

13.

Erickson L, Mete O . Immunohistochemistry in Diagnostic Parathyroid Pathology. Endocr Pathol. 2018; 29(2):113-129. DOI: 10.1007/s12022-018-9527-6. View

14.

Yun C, Kim H, Lim J, Lee S . Heat Shock Proteins: Agents of Cancer Development and Therapeutic Targets in Anti-Cancer Therapy. Cells. 2019; 9(1). PMC: 7017199. DOI: 10.3390/cells9010060. View

15.

Akpinar G, Kasap M, Canturk N, Zulfigarova M, Islek E, Guler S . Proteomics Analysis of Tissue Samples Reveals Changes in Mitochondrial Protein Levels in Parathyroid Hyperplasia over Adenoma. Cancer Genomics Proteomics. 2017; 14(3):197-211. PMC: 5420820. DOI: 10.21873/cgp.20031. View

16.

Hibi K, Liu Q, Beaudry G, Madden S, Westra W, Wehage S . Serial analysis of gene expression in non-small cell lung cancer. Cancer Res. 1998; 58(24):5690-4. View

17.

Walker M, Silverberg S . Primary hyperparathyroidism. Nat Rev Endocrinol. 2017; 14(2):115-125. PMC: 6037987. DOI: 10.1038/nrendo.2017.104. View

18.

Brewer K, Costa-Guda J, Arnold A . Molecular genetic insights into sporadic primary hyperparathyroidism. Endocr Relat Cancer. 2018; 26(2):R53-R72. DOI: 10.1530/ERC-18-0304. View

19.

Ashtekar A, Huk D, Magner A, Perle K, Boucai L, Kirschner L . Alterations in Sod2-Induced Oxidative Stress Affect Endocrine Cancer Progression. J Clin Endocrinol Metab. 2018; 103(11):4135-4145. PMC: 6194813. DOI: 10.1210/jc.2018-01039. View

20.

Ciregia F, Giusti L, Molinaro A, Niccolai F, Mazzoni M, Rago T . Proteomic analysis of fine-needle aspiration in differential diagnosis of thyroid nodules. Transl Res. 2016; 176:81-94. DOI: 10.1016/j.trsl.2016.04.004. View